Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Investigational New Drugs

Volumn 32, Issue 4, 2014, Pages 670-681

  Rodon, Jordi ^a,b   Braña, Irene ^a,b   Siu, Lillian L ^c   De Jonge, Maja J ^d   Homji, Natasha ^e   Mills, David ^e   Di Tomaso, Emmanuelle ^f   Sarr, Celine ^e   Trandafir, Lucia ^g   Massacesi, Cristian ^g   Eskens, Ferry ^d   Bendell, Johanna C ^h  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^g Novartis Oncology   (France)

^h SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

BKM120; Buparlisib; Oncology; PI3K inhibitor; Solid tumors; Targeted therapy

Indexed keywords

AMINOPYRIDINE DERIVATIVE; MORPHOLINE DERIVATIVE; NVP-BKM120; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; AMINOPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORPHOLINES; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84904555503     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0082-9     Document Type: Article

References (45)

1. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627-644
2. Huang WC, Hung MC (2009) Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 108(3):180-194
3. Nahta R, O'Regan RM (2010) Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer 10(Suppl 3):S72-S78
4. Miller TW, Balko JM, Arteaga CL (2011) Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29(33):4452-4461
5. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J et al (2009) PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 8(1):21-26
6. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28(6):1075-1083
7. The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068
8. Cancer Genome Atlas Research Network, Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R et al (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519-525
9. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70
10. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D et al (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11(2):317-328
11. Koul D, Shen R, LaFortune TA, Tiao N, KimYW, Liu JL et al (2010) NVP-BKM120: a selective pan-PI3 kinase inhibitor induces G2/M arrest in glioma cell lines via FOXO3a and GADD45a loop. American Association for Cancer Research Congress. [abstract 350]
12. Schnell CR, Arnal S, Becquet M, Allegrini P, Voliva C, Cozens R et al (2010) NVP-BKM120, a pan class I PI3K inhibitor impairs microvascular permeability and tumor growth as detected by DCEMRI and IFP measurements via radio-telemetry: comparison with NVP-BEZ235. American Association for Cancer Research Congress. [abstract 4472]
13. Maira M, Menezes D, Pecchi S, Shoemaker K, Burger M, Schnell C et al (2010) NVP-BKM120, a novel inhibitor of phosphoinosotide 3- kinase in phase I/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models. AACR Meeting Abstracts. 4497 (abstract)
14. Voliva CF, Pecchi S, Burger M, Nagel T, Schnell C, Fritsch C et al (2010) Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in phase I/II clinical trials. AACR Meeting Abstracts 4498 (abstract)
15. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D et al (2012) Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30(3):282-290
16. Spitzer RL, Kroenke K, Williams JB, Lowe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166(10):1092-1097 (Pubitemid 43765180)
17. Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16(9):606-613 (Pubitemid 32823891)
18. Babb J, Rogatko A, Zacks S (1998) Cancer Phase I clinical trials: efficient dose escalation with overdose control. Stat Med 17(10):1103-1120 (Pubitemid 28221028)
19. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. european organization for research and treatment of cancer (EORTC) PET study group. Eur J Cancer 35(13):1773-1782 (Pubitemid 29512308)
20. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E et al (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth andmetabolic regulation. Nature 441(7091):366-370 (Pubitemid 44050203)
21. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7(2):85-96 (Pubitemid 43278292)
22. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O et al (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125(4):733-747
23. Von Hoff DD, LoRusso P, Tibes R, Shapiro G, Weiss GJ, Ware JA et al (2010) A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. ASCO Meeting Abstracts 28(15-suppl):2541
24. Peyton JD, Rodon Ahnert J, Burris H, Britten C, Chen LC, Tabernero J et al (2011) A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. ASCO Meeting Abstracts 29(15-suppl):3066
25. Wagner AJ, Bendell JC, Dolly S, Morgan JA, Ware JA, Fredrickson J et al (2011) A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol 29(suppl):abstract 3020 (poster presentation)
26. Munster PN, van der Noll R, Voest EE, Dees EC, Tan AR, Specht JM et al (2011) Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). ASCO Meeting Abstracts 29(15-suppl):3018
27. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML et al (2012) Multiorgan metastasis of human HER-2(+) breast cancer in Rag2(-/-);Il2rg(-/-) mice and treatment with PI3K inhibitor. PLoS One 7(6):e39626
28. Tohda C, Nakanishi R, Kadowaki M (2009) Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85alpha subunit of phosphoinositide-3 kinase. Brain Dev 31(1):69-74
29. Ackermann TF, Hortnagl H, Wolfer DP, Colacicco G, Sohr R, Lang F et al (2008) Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala. Cell Physiol Biochem 22(5-6):735-744
30. Kalkman HO (2006) The role of the phosphatidylinositide 3-kinaseprotein kinase B pathway in schizophrenia. Pharmacol Ther 110(1):117-134
31. A phase I dose escalation study of BKM120 with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma - ClinicalTrials.gov (NCT01473901) [homepage on the Internet]. [cited 4/3/2013]
32. Safety and efficacy of BKM120 in combination with trastuzumab in patients with relapsing HER2 overexpressing breast cancer who have previously failed trastuzumab - ClinicalTrials.gov (NCT01132664) [homepage on the Internet]. [cited 4/3/2013]
33. Mortazavi-Jehanno N, Giraudet AL, Champion L, Lerebours F, Le Stanc E, Edeline V et al (2012) Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 39(3):450-460
34. Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ et al (2011) Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 17(10):3304-3315
35. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB et al (2012) Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30(14):1628-1634
36. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J et al (2012) Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer. Cancer Discov 2(11):1048-1063
37. Kelly CJ, Hussien K, Muschel RJ (2012) 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PETas an early indicator of response to PI3K inhibition. Nucl Med Biol 39(7):986-992
38. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T et al (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120(8):2858-2866
39. Rexer BN, Chanthaphaychith S, Dahlman KB, Arteaga CL (2014) Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res 16(1):R9
40. Juric D, Rodon J, Gonzalez-Angulo AM, Burris HA, Bendell J, Berlin JD et al (2012) In: BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d14acbff-7602-45e9- a577-11db6325068e&cKey=04a16b3b-4956-4cf9-833f-b223331f46b4&mKey= {2D8C569E-B72C-4E7D-AB3B-070BEC7EB280}. p. Abstract nr CT-01
41. Huang A, Fritsch C, Wilson C, Reddy A, Liu M, Lehar J et al (2012) Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR Abstract nr 3749
42. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH et al (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454(7205):776-779
43. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, de Beaumont R et al (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 105(35):13057-62
44. Juric D, Baselga J (2012) Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors. J Clin Oncol 30(8):765-766
45. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550-562